Search alternatives:
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
mg decrease » _ decrease (Expand Search), we decrease (Expand Search), mean decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
2 step » _ step (Expand Search), a step (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
mg decrease » _ decrease (Expand Search), we decrease (Expand Search), mean decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
2 step » _ step (Expand Search), a step (Expand Search)
-
1641
Induction of ER stress does not lead to a MG phenotype.
Published 2011“…<p>(A–B) S2 cells were treated with vehicle (0.1% DMSO), 10 µg/ml tunicamycin (TUN), 1 µM thapsigargin (THA) and 5 mM DTT for 24 h, fixed and processed for IF. …”
-
1642
-
1643
The prevalence of hypertension, diabetes, metabolic syndrome, cardiovascular disease and decreased GFR according to the following age groups: 60–69, 70–79 and ≥80 years.
Published 2017“…Diabetes mellitus: self-reported or a fasting plasma glucose ≥126 mg/dL or a glycohemoglobin ≥6.5%. …”
-
1644
Effects of conivaptan on brain water content (BWC), blood-brain-barrier (BBB) disruption, plasma and urine sodium and osmolality.
Published 2015“…Following MCAO, Evans Blue (EB) extravasation index (I/C) was increased in vehicle treated mice, and reduced in conivaptan treated mice, naïve, n = 5, vehicle, n = 8, Conivaptan 0.2 mg, n = 8. (C, D) Conivaptan treatment of 0.2 mg resulted in an elevation of plasma sodium and osmolality, and decreased urine sodium and osmolality due to aquaresis. …”
-
1645
-
1646
-
1647
Absence of caveolin-1 decreases KCa2.3 endocytosis.
Published 2013“…</b> Knockout of caveolin-1 (Cav-1(−/−)) resulted in a significant decrease of KCa2.3 endocytosis, relative to WT MEFs (n = 3; *p<0.05). …”
-
1648
-
1649
-
1650
-
1651
-
1652
FTY720 decreased viability, proliferation, and motility and induced apoptosis in human hepatoblastoma cells.
Published 2019“…(B) Following 24 hours of treatment with FTY720, the proliferation of HuH6 cells measured using the CellTiter 96 cell proliferation assay was significantly decreased (IC<sub>50</sub> = 6.4 μM, p ≤ 0.05). (C) HuH6 cells were plated and allowed to reach 80% confluence, at which time the media was changed for fresh media (0, 5, or 8 μM FTY720) and a standard scratch wound was made. …”
-
1653
-
1654
-
1655
Low-dosage sDll4-Fc does not affect perfusion levels and leads to only a small increase in extravasation while higher dosages cause decreased perfusion and highly increased extrava...
Published 2012“…<p>A) Representative anti-PECAM and anti-Lectin immunofluorescence images of neo-vasculature in granulation tissue of wounds treated with 0,05 mg/kg or 2,5 mg/kg compared with control mice injected with PBS, in day 6. …”
-
1656
Table_1_Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to...
Published 2022“…Patients with baseline cirrhosis (2.78 ± 2.56 vs. 6.84 ± 9.00 mg/dL, p=0.024) and UDCA nonresponders (2.54 ± 2.19 vs. 4.51 ± 6.99 mg/dL, p=0.006) had increased total bilirubin levels while patients without cirrhosis (AST: 91.5 ± 84.5 vs. 58.9 ± 43.7 U/L, p<0.001; ALT: 107.3 ± 122.5 vs. 50.7 ± 36.8 U/L, p<0.001) and UDCA responders (AST: 83.8 ± 101.3 vs. 45.58 ± 38.42 U/L, p=0.014; ALT: 95.10 ± 144.6 vs. 39.12 ± 30.65 U/L, p=0.009) had decreased aminotransferase levels. …”
-
1657
Image_1_Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to...
Published 2022“…Patients with baseline cirrhosis (2.78 ± 2.56 vs. 6.84 ± 9.00 mg/dL, p=0.024) and UDCA nonresponders (2.54 ± 2.19 vs. 4.51 ± 6.99 mg/dL, p=0.006) had increased total bilirubin levels while patients without cirrhosis (AST: 91.5 ± 84.5 vs. 58.9 ± 43.7 U/L, p<0.001; ALT: 107.3 ± 122.5 vs. 50.7 ± 36.8 U/L, p<0.001) and UDCA responders (AST: 83.8 ± 101.3 vs. 45.58 ± 38.42 U/L, p=0.014; ALT: 95.10 ± 144.6 vs. 39.12 ± 30.65 U/L, p=0.009) had decreased aminotransferase levels. …”
-
1658
p35 siRNA knockdown decreased Cdk5 activity, diminished WT1 expression and viable cell numbers, but did not affect a cell apoptosis marker as detected by WB.
Published 2016“…A&B. Western blots show that p35 siRNA-transfected podocytes successfully decrease p35 expression (upper panel, lane 2) compared to the control siRNA cells (p<0.05), but did not affect cyclin I expression (3<sup>rd</sup> panel). …”
-
1659
-
1660